Fig. 2 | Scientific Reports

Fig. 2

From: Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway

Fig. 2

Synergistic effect of tafasitamab plus metronomic chemotherapy. Combination index (CI)-fraction affected plot of 144 h metronomic vinorelbine (VNR) + tafasitamab (TAFA) (A) and metronomic etoposide (ETO) + tafasitamab (B) concomitant combination in Toledo, OCI-LY3 and SU-DHL10 cells. CI < 1, CI = 1 and CI > 1 indicate synergism, additive effect and antagonism, respectively. Three-dimensional landscape of the dose matrix of combination responses on the Loewe model, of 144 h metronomic vinorelbine (VNR) + tafasitamab (C, E, G) and metronomic etoposide (ETO) + tafasitamab (D, F, H) concomitant combination in Toledo (C, D), OCI-LY3 (E, F) and SU-DHL10 (G, H) cells. Blue and red colour reflect evidence of synergy and antagonism, respectively. The model supported synergy of the combination in reducing cells viability. Cell viability was plotted as % human IgG1 isotype control.

Back to article page